More Drug Price Disclosure In Store As WHO Delegates Pass Landmark Resolution
Many see the World Health Assembly resolution on drug pricing transparency as a game changer and welcome the fact that it will shine light on an area that critics says is far too opaque. Some are unhappy that the final version is not as strong as the original draft, but industry will be relieved the WHA ultimately did not adopt a requirement for mandatory disclosure of R&D costs.
You may also be interested in...
The signs suggest that Nicola Magrini, the new director general of the Italian medicines regulator, AIFA, will follow in the footsteps of his predecessor in fighting for transparency in drug pricing.
Civil society groups have welcomed a French parliamentary amendment that would require pharma firms to disclose any public R&D funding when negotiating drug prices with the health authorities. The pharmaceutical industry says the amendment does not take account of the realities of today's business model.
Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.